Dechert Advises Royalty Pharma on Acquisition of Additional Royalty Interest from the Cystic Fibrosis Foundation
November 02, 2020
Dechert is advising Royalty Pharma plc on IP-related matters in its agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
The Dechert team advising Royalty Pharma includes intellectual property partner Carl A. Morales, Ph.D., associate Blaine M. Hackman, Ph.D. and patent agent Todd K. Macklin, Ph.D.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for all clients.
Related Professionals
